title: Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.
abstract: While the proportion of patients with significant statin-associated adverse effects or intolerance is very low, the increasing use and broadening indications have led to a significant absolute number of such patients commonly referred to tertiary care facilities and specialists. This report provides a comprehensive overview of the evidence pertaining to a broad variety of statin-associated adverse effects followed by a consensus approach for the prevention, assessment, diagnosis, and management. The overview is intended both to provide clarification of the untoward effects of statins and to impart confidence in managing the most common issues in a fashion that avoids excessive ancillary testing and/or subspecialty referral except when truly necessary. The ultimate goal is to ensure that patients who warrant cardiovascular risk reduction can be treated optimally, safely, and confidently with statin medications or alternatives when warranted.
authors.affiliation: Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. mancini@interchange.ubc.ca
authors.forename: G B John
authors.initials: GB
authors.lastname: Mancini
authors.forename: Steven
authors.initials: S
authors.lastname: Baker
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.forename: David
authors.initials: D
authors.lastname: Fitchett
authors.forename: Jiri
authors.initials: J
authors.lastname: Frohlich
authors.forename: Jacques
authors.initials: J
authors.lastname: Genest
authors.forename: Milan
authors.initials: M
authors.lastname: Gupta
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hegele
authors.forename: Dominic
authors.initials: D
authors.lastname: Ng
authors.forename: Janet
authors.initials: J
authors.lastname: Pope
mesh_terms: D002170:Canada; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors